CARACAS, VENEZUELA – LataMed AI Corp. (OTC: LMED), a healthcare technology company specializing in digital health and artificial intelligence solutions for Latin America, announced today that its Venezuelan subsidiary, LATAMEDAI VE, has entered into a memorandum of understanding (MOU) with FARMASER to develop a customized artificial intelligence and automation platform designed to support the pharmacy chain’s current operations and planned expansion.
Under the MOU, the companies will collaborate on designing, adapting, testing, and evaluating a software platform tailored to FARMASER’s operational requirements. The initial phase will involve defining technical and operational specifications, adapting the software to FARMASER’s pharmacy workflows, and establishing a phased development and testing process.
A key component of the proposed platform includes the potential integration of LataMed AI’s CardioAI, PulmoAI, and NeuroAI models across FARMASER’s three existing pharmacy locations and up to 15 planned additional sites. These AI-supported platforms are intended to assist healthcare professionals in evaluating cardiovascular, pulmonary, and neurological health information. The integration would also encompass e-commerce, prescription management, customer service, inventory planning, and business analytics functions.
Dr. Kevin Rodan Levy, CEO of LataMed AI Corp., emphasized the strategic importance of the partnership. “Pharmacies play a central role in connecting patients with medications, healthcare products, and related services,” he said. “Our objective is to work with FARMASER to develop a platform that supports its current operations and planned expansion while evaluating the integration of our AI-supported healthcare technologies across its pharmacy network.”
The MOU also calls for evaluating an annual software licensing or subscription model for any commercial implementation. However, the scope, timing, pricing, and other terms of a commercial deployment have not been finalized and remain subject to successful development, testing, and agreement on definitive commercial terms.
This collaboration represents a potential expansion of LataMed AI’s technology beyond its patient-facing telemedicine services into enterprise applications. By supporting pharmacy operations, digital commerce, prescription workflows, and data analysis, LataMed AI aims to develop infrastructure adaptable to other healthcare organizations throughout Latin America.
The integration of AI-supported functionality is designed to assist administrative, operational, and healthcare workflows, not to replace the professional judgment of authorized pharmacists, medical professionals, or other qualified personnel. Any prescription-related or AI-supported features would be subject to continued development, testing, applicable regulatory requirements, and appropriate clinical and operational protocols.
Management believes this initiative aligns with LataMed AI’s broader strategy of creating an integrated healthcare ecosystem connecting patients, healthcare professionals, pharmacies, insurers, payment providers, and other stakeholders. The MOU establishes a framework for cooperation but does not guarantee successful completion or commercial deployment of the platform, integration of AI technologies, execution of a definitive licensing agreement, opening of additional FARMASER locations, or revenue generation.
For additional information, visit LataMed AI’s website or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
